Sign In
Buy ANNX
$5.39
+0.130 (+2.47%)
At Close: Jun 03, 2026
How Much Upside is Left in Annexon, Inc. (ANNX)? Wall Street Analysts Think 246%
02:55pm, Tuesday, 15'th Nov 2022 Zacks Investment Research
The mean of analysts' price targets for Annexon, Inc. (ANNX) points to a 246.1% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
Annexon Reports Third Quarter 2022 Financial Results and Plans to Provide Updates on Complement Therapeutic Portfolio in January 2023
10:30am, Thursday, 03'rd Nov 2022 GlobeNewswire Inc.
Company to provide portfolio updates across autoimmune, neurodegeneration and ophthalmology therapeutic franchises in early January
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
08:01pm, Friday, 16'th Sep 2022 GlobeNewswire Inc.
BRISBANE, Calif., Sept. 16, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classic
Benzinga's Top Ratings Upgrades, Downgrades For September 16, 2022
02:04pm, Friday, 16'th Sep 2022 Benzinga
Upgrades
Morgan Stanley upgraded the previous rating for Alcoa Corp (NYSE:AA) from Equal-Weight to Overweight. Alcoa earned $2.67 in the second quarter, compared to $1.49 in the year-ago quarter. The
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
02:40pm, Friday, 09'th Sep 2022 Benzinga
Upgrades
For 3M Co (NYSE:MMM), UBS upgraded the previous rating of Sell to Neutral. For the second quarter, 3M had an EPS of $2.48, compared to year-ago quarter EPS of $2.59. The current stock perform
Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
08:05pm, Wednesday, 17'th Aug 2022 GlobeNewswire Inc.
BRISBANE, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
Annexon Biosciences Highlights Business and Portfolio Progress and Key Anticipated Milestones and Reports Second Quarter 2022 Financial Results
08:01pm, Monday, 08'th Aug 2022 GlobeNewswire Inc.
Advancing Robust Pipeline of Five Clinical-Stage Product Candidates Following ANX105 and ANX1502 Phase 1 Trial Initiations
Annexon Closes $130 Million Private Placement Extending its Operating Runway into the Second Half of 2025
10:25pm, Monday, 11'th Jul 2022 GlobeNewswire Inc.
Proceeds Support Advancement of Broad Pipeline of Novel Complement Product Candidates for Diseases of the Body, Brain and Eye Proceeds Support Advancement of Broad Pipeline of Novel Complement Product
Tesla, Twitter And 76 Biggest Movers From Friday
11:30am, Monday, 11'th Jul 2022 Benzinga
Gainers
Seritage Growth Properties (NYSE: SRG) shares surged 80.3% to settle at $10.96 after the company appointed Adam Metz as Chairman. Preliminary proxy materials also indicated the board recomme
Tesla, WD-40 Company And 40 Stocks Moving In Friday's Mid-Day Session
04:20pm, Friday, 08'th Jul 2022 Benzinga
Gainers
Aditxt, Inc. (NASDAQ: ADTX) shares surged 75.7% to $0.2812 after the company's Adimune therapeutic program completed a toxicology study indicating a favorable safety profile of ADI-100.
Serit
Best Penny Stocks To Buy Now? 4 To Watch After Jobs Report
02:33pm, Friday, 08'th Jul 2022 PennyStocks
Penny stocks to buy or avoid? You be the judge after today's jobs report.
The post Best Penny Stocks To Buy Now? 4 To Watch After Jobs Report appeared first on Penny Stocks to Buy, Picks, News and Inf
Annexon Announces $130 Million Private Placement Financing
11:00am, Friday, 08'th Jul 2022 GlobeNewswire Inc.
BRISBANE, Calif., July 08, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
Annexon Touts Final Huntington's Trial Data Confirming No New Safety Issues
12:29pm, Tuesday, 07'th Jun 2022
Annexon Inc (NASDAQ: ANNX) shared final data from the Phase 2 trial for ANX005 in patients with or at risk for Huntington's disease, which causes a progressive breakdown of nerve cells in the brain
Annexon Biosciences Reports Phase 2 Clinical Trial Results Demonstrating Upstream Classical Complement Inhibition Associated with Clinical Benefit in Huntington’s Disease
10:30am, Tuesday, 07'th Jun 2022 GlobeNewswire Inc.
ANX005 Demonstrated Full C1q Target Inhibition and Was Generally Well-Tolerated
Annexon Biosciences to Present at the 2022 Jefferies Healthcare Conference
10:30am, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
BRISBANE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement medicines for patients with classica
